Title : Transient prenatal ruxolitinib treatment suppresses astrogenesis during development and improves learning and memory in adult mice.

Pub. Date : 2021 Feb 15

PMID : 33589712






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Ruxolitinib is the first janus kinase 1 (JAK1) and JAK2 inhibitor that was approved by the United States Food and Drug Administration (FDA) agency for the treatment of myeloproliferative neoplasms. ruxolitinib Janus kinase 2 Mus musculus